Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The trial terminated due to the inability to recruit the planned number of subjects. The decision was not based on any safety and/or efficacy concerns

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Maplirpacept
DRUG: Tafasitamab
DRUG: Lenalidomide

Sponsor

Pfizer

Collaborators

[object Object]
[object Object]